May 31, 2018 + Jessica Di Palo
5 Min read
May 8th, 2018 saw a gathering of leaders from all of the MTIP portfolio companies to discuss how their companies are responding to the challenging and ever changing healthcare environment.
Christoph Kausch, MTIP’s Managing Partner, described how the business model of healthcare is changing from a centralised, fee for service based model into the decentralised, fee for result model that is dominated by outcomes data.
In front of an audience including over 40 investor and healthcare professionals, leaders from Reactive Robotics, Coramaze, Blueprint Genetics, TytoCare and Nitinotes joined in a panel discussion and shared their views on how to succeed and create value. It was the first time that our portfolio leaders had met, and beyond enjoying a networking opportunity with many of the interested audience, they also had an opportunity to discuss strategies and business problems amongst their fellow C-level colleagues.
MTIP’s first Healthcare Clinic was just another way that we bring together the best and brightest people, creating a community of health care professionals that all share the goal of creating successful healthcare companies.
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio
MTIP invests in Lumeon Ltd.
New investment in Lumeon
Magenverkleinerung mit der Handnähmaschine
Nitinotes news paper article
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta
MTIP’s Healthcare Clinic 2018
Healthcare Clinic 2018
Interview with Christoph Kausch in biotechandmoney
New MTIP investment – Nitinotes Series A Round
New investment in Nitinotes
New investment in an Israeli based digital health company TytoCare
New investment in TytoCare
MTIP joins United Nations-supported Principles for Responsible Investments
MTIP signs Principles for Responsible Investments
MTIP invests in Blueprint Genetics
new investment in Blueprint Genetics